Myeloperoxidase Inhibition Improves Ventricular Function and Remodeling After Experimental Myocardial Infarction

Muhammad Ali; Benjamin Pulli; Gabriel Courties; Benoit Tricot; Matthew Sebas; Yoshiko Iwamoto; Ingo Hilgendorf; Stefan Schob; Anping Dong; Wei Zheng; Athanasia Skoura; Amit Kalgukar; Christian Cortes; Roger Ruggeri; Filip K. Swirski; Matthias Nahrendorf; Leonard Buckbinder; John W. Chen

doi:10.1016/j.jacbts.2016.09.004

Myeloperoxidase Inhibition Improves Ventricular Function and Remodeling After Experimental Myocardial Infarction

Muhammad Ali
, Benjamin Pulli
, Gabriel Courties
, Benoit Tricot
, Matthew Sebas
, Yoshiko Iwamoto
, Ingo Hilgendorf
, Stefan Schob
, Anping Dong
, Wei Zheng
, Athanasia Skoura
, Amit Kalgukar
, Christian Cortes
, Roger Ruggeri
, Filip K. Swirski
, Matthias Nahrendorf
, Leonard Buckbinder
, John W. Chen

Research output: Contribution to journal › Review article › peer-review

108 Scopus citations

Abstract

PF-1355 is an oral myeloperoxidase (MPO) inhibitor that successfully decreased elevated MPO activity in mouse myocardial infarction models. Short duration PF-1355 treatment for 7 days decreased the number of inflammatory cells and attenuated left ventricular dilation. Cardiac function and remodeling improved when treatment was increased to 21 days. Better therapeutic effect was further achieved with early compared with delayed treatment initiation (1 h vs. 24 h after infarction). In conclusion, PF-1355 treatment protected a mouse heart from acute and chronic effects of MI, and this study paves the way for future translational studies investigating this class of drugs in cardiovascular diseases.

Original language	English
Pages (from-to)	633-643
Number of pages	11
Journal	JACC: Basic to Translational Science
Volume	1
Issue number	7
DOIs	https://doi.org/10.1016/j.jacbts.2016.09.004
State	Published - 2016
Externally published	Yes

Keywords

inflammation
myeloperoxidase
myocardial infarction
oxidative stress
treatment

Access to Document

10.1016/j.jacbts.2016.09.004

Cite this

Ali, M., Pulli, B., Courties, G., Tricot, B., Sebas, M., Iwamoto, Y., Hilgendorf, I., Schob, S., Dong, A., Zheng, W., Skoura, A., Kalgukar, A., Cortes, C., Ruggeri, R., Swirski, F. K., Nahrendorf, M., Buckbinder, L., & Chen, J. W. (2016). Myeloperoxidase Inhibition Improves Ventricular Function and Remodeling After Experimental Myocardial Infarction. JACC: Basic to Translational Science, 1(7), 633-643. https://doi.org/10.1016/j.jacbts.2016.09.004

@article{39964856cb594637a80dd60390c07715,

title = "Myeloperoxidase Inhibition Improves Ventricular Function and Remodeling After Experimental Myocardial Infarction",

abstract = "PF-1355 is an oral myeloperoxidase (MPO) inhibitor that successfully decreased elevated MPO activity in mouse myocardial infarction models. Short duration PF-1355 treatment for 7 days decreased the number of inflammatory cells and attenuated left ventricular dilation. Cardiac function and remodeling improved when treatment was increased to 21 days. Better therapeutic effect was further achieved with early compared with delayed treatment initiation (1 h vs. 24 h after infarction). In conclusion, PF-1355 treatment protected a mouse heart from acute and chronic effects of MI, and this study paves the way for future translational studies investigating this class of drugs in cardiovascular diseases.",

keywords = "inflammation, myeloperoxidase, myocardial infarction, oxidative stress, treatment",

author = "Muhammad Ali and Benjamin Pulli and Gabriel Courties and Benoit Tricot and Matthew Sebas and Yoshiko Iwamoto and Ingo Hilgendorf and Stefan Schob and Anping Dong and Wei Zheng and Athanasia Skoura and Amit Kalgukar and Christian Cortes and Roger Ruggeri and Swirski, \{Filip K.\} and Matthias Nahrendorf and Leonard Buckbinder and Chen, \{John W.\}",

note = "Publisher Copyright: {\textcopyright} 2016 The Authors",

year = "2016",

doi = "10.1016/j.jacbts.2016.09.004",

language = "English",

volume = "1",

pages = "633--643",

journal = "JACC: Basic to Translational Science",

issn = "2452-302X",

publisher = "Elsevier Inc.",

number = "7",

}

Ali, M, Pulli, B, Courties, G, Tricot, B, Sebas, M, Iwamoto, Y, Hilgendorf, I, Schob, S, Dong, A, Zheng, W, Skoura, A, Kalgukar, A, Cortes, C, Ruggeri, R, Swirski, FK, Nahrendorf, M, Buckbinder, L & Chen, JW 2016, 'Myeloperoxidase Inhibition Improves Ventricular Function and Remodeling After Experimental Myocardial Infarction', JACC: Basic to Translational Science, vol. 1, no. 7, pp. 633-643. https://doi.org/10.1016/j.jacbts.2016.09.004

TY - JOUR

T1 - Myeloperoxidase Inhibition Improves Ventricular Function and Remodeling After Experimental Myocardial Infarction

AU - Ali, Muhammad

AU - Pulli, Benjamin

AU - Courties, Gabriel

AU - Tricot, Benoit

AU - Sebas, Matthew

AU - Iwamoto, Yoshiko

AU - Hilgendorf, Ingo

AU - Schob, Stefan

AU - Dong, Anping

AU - Zheng, Wei

AU - Skoura, Athanasia

AU - Kalgukar, Amit

AU - Cortes, Christian

AU - Ruggeri, Roger

AU - Swirski, Filip K.

AU - Nahrendorf, Matthias

AU - Buckbinder, Leonard

AU - Chen, John W.

PY - 2016

Y1 - 2016

N2 - PF-1355 is an oral myeloperoxidase (MPO) inhibitor that successfully decreased elevated MPO activity in mouse myocardial infarction models. Short duration PF-1355 treatment for 7 days decreased the number of inflammatory cells and attenuated left ventricular dilation. Cardiac function and remodeling improved when treatment was increased to 21 days. Better therapeutic effect was further achieved with early compared with delayed treatment initiation (1 h vs. 24 h after infarction). In conclusion, PF-1355 treatment protected a mouse heart from acute and chronic effects of MI, and this study paves the way for future translational studies investigating this class of drugs in cardiovascular diseases.

AB - PF-1355 is an oral myeloperoxidase (MPO) inhibitor that successfully decreased elevated MPO activity in mouse myocardial infarction models. Short duration PF-1355 treatment for 7 days decreased the number of inflammatory cells and attenuated left ventricular dilation. Cardiac function and remodeling improved when treatment was increased to 21 days. Better therapeutic effect was further achieved with early compared with delayed treatment initiation (1 h vs. 24 h after infarction). In conclusion, PF-1355 treatment protected a mouse heart from acute and chronic effects of MI, and this study paves the way for future translational studies investigating this class of drugs in cardiovascular diseases.

KW - inflammation

KW - myeloperoxidase

KW - myocardial infarction

KW - oxidative stress

KW - treatment

UR - https://www.scopus.com/pages/publications/85016117240

U2 - 10.1016/j.jacbts.2016.09.004

DO - 10.1016/j.jacbts.2016.09.004

M3 - Review article

AN - SCOPUS:85016117240

SN - 2452-302X

VL - 1

SP - 633

EP - 643

JO - JACC: Basic to Translational Science

JF - JACC: Basic to Translational Science

IS - 7

ER -

Myeloperoxidase Inhibition Improves Ventricular Function and Remodeling After Experimental Myocardial Infarction

Abstract

Keywords

Access to Document

Fingerprint

Cite this